Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Adjuvant treatment duration for high-risk stage II colon cancer

HORG trial

Date

30 Sep 2019

Session

Adjuvant treatment duration for high-risk stage II colon cancer

Topics

Tumour Site

Oesophageal Cancer;  Gastric Cancer;  Anal Cancer;  Hepatobiliary Cancers;  Pancreatic Adenocarcinoma;  Colon and Rectal Cancer

Presenters

Ioannis Souglakos

Authors

I. Souglakos

Author affiliations

  • Medical Oncology Dept, University Hospital of Heraklion (PAGNI), 715 00 - Heraklion/GR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.